UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2019
Commission File Number 001-38370
CollPlant Biotechnologies Ltd.
(Exact name of registrant as specified in
its charter)
4 Oppenheimer St, Weizmann Science Park
Rehovot 7670104, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ¨
This Report on Form 6-K (excluding Exhibit
99.1) is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-229163)
and Form F-3 (File No. 333-229486 and 333-228054), to be a part thereof from the date on which this report is submitted, to the
extent not superseded by documents or reports subsequently filed or furnished.
On August 30, 2019, CollPlant
Biotechnologies Ltd. (the “Company”) entered into (i) a Convertible Loan Agreement with Ami Sagi,
a major shareholder of the Company (the “Sagi Loan Agreement”), pursuant to which Ami Sagi agreed, upon the
terms and subject to the conditions of the Sagi Loan Agreement, to provide a loan to the Company in an amount of $3,000,000 in
two tranches, and (ii) a Convertible Loan Agreement with certain U.S. investors (the “U.S. Loan Agreement”, and,
together with the Sagi Loan Agreement, the “Convertible Loan Agreements”), pursuant to which such U.S. investors
(the “U.S. Investors”) agreed, upon the terms and subject to the conditions of the U.S. Loan Agreement, to provide
a loan to the Company in an amount of $3,500,000 in one tranche.
The Sagi Loan Agreement provides that the
transactions contemplated by the Sagi Loan Agreement shall occur in three separate closings. On the first closing date, which occurred
on September 3, 2019, Ami Sagi transferred to the Company the principal amount of $2,000,000 (the “First Principal Amount”).
On the second closing date, which will occur three business days after the Company shall have executed a license and/or a co-development
agreement with a certain strategic business partner of the Company with respect to the Company’s intellectual property (if
such were to occur) (the “Second Closing Date”), the following shall occur: (i) Ami Sagi will transfer to the
Company the principal amount of $1,000,000 (the “Second Principal Amount”), and (ii) if the Second Closing Date shall
occur after the Third Closing Date (as defined below), the Company will issue to Ami Sagi a warrant to purchase up to 250,000 American
Depositary Shares (“ADSs”) representing 250,000 ordinary shares (the “Second Closing Warrant”). On the
third closing date, which will occur three business days after the Company shall have received shareholder approval (the “Shareholder
Approval”) approving the holding by Ami Sagi of voting rights in the Company exceeding 25% of the voting rights in the Company
as well as the implementation of existing anti-dilution undertakings of the Company towards Ami Sagi, Alpha Capital Anstalt and
Meitav Dash Provident Funds and Pension Ltd (the “Third Closing Date”), the following shall occur (i) the First Principal
Amount and the Second Principal Amount (to the extent applicable) will automatically be converted into ADSs at a conversion price
equal to $4.00 per ADS, and the Company shall pay to Ami Sagi the interest accrued on the converted principal in cash, (ii) the
Company will issue to Ami Sagi a warrant to purchase up to 500,000 ADSs representing 500,000 ordinary shares, and, (iii) if the
Second Closing Date shall have occurred prior to the Third Closing Date, the Company will issue to Ami Sagi the Second Closing
Warrant. In addition, if the Third Closing Date occurs before the Second Closing Date, the payment of $1,000,000 (to the extent
the Second Closing is completed) shall be made by way of an equity investment in the Company, and not by way of a convertible loan,
at a price equal to $4.00 per ADS.
The U.S. Loan Agreement provides that the
transactions contemplated by the U.S. Loan Agreement shall occur in two separate closings. On the first closing date, which is
expected to occur by September 5, 2019 subject to the satisfaction of customary closing conditions, the U.S. Investors shall transfer
to the Company the principal amount of $3,500,000 (“Principal Amount”). On the second closing date, which will occur
three business days after the Company shall have received Shareholder Approval, the following shall occur: (i) the Principal Amount
will automatically be converted into ADSs at a conversion price equal to $4.00 per ADS, and the Company shall pay the U.S. Investors
the interest accrued on the converted principal in cash, and (ii) the Company will issue the U.S. Investors warrants to purchase
up to an aggregate amount of 875,000 ADSs representing 875,000 ordinary shares, at an exercise price of $4.00 per ADS.
The loans issuable under the Convertible
Loan Agreements have a maturity date of three years from the issuance of the loan and bear interest at the rate of 6% per annum,
payable in arrears on a quarterly basis. The principal amount of the loans will automatically convert into ADSs at a conversion
$4.00 per ADS on the occurrence of the conditions described above. The loans may be prepaid early without any penalty and upon
the occurrence of certain events of default, the outstanding loan amount, will become, at the election of each lender, immediately
due and payable. The loans are subject to certain adjustments upon certain events, including share splits and share dividends.
In addition, until the three-year anniversary of the first closing date and so long as the principal amount under the loans has
not converted into ADSs, in the event of certain subsequent equity issuances at a price that is lower than the then applicable
conversion price, the conversion price shall adjust to such lower price.
In addition, on the third closing date
(in the case of Ami Sagi) and the second closing date (in the case of the U.S. Investors), the Company agreed to enter into Price
Protection Agreements pursuant to which, until the three-year anniversary of the first closing date, the Company shall issue additional
ADSs in the event of certain subsequent equity issuances at a price that is lower than $4.00 (subject to certain adjustments) on
a “full-ratchet” basis with respect to their holdings in the Company.
The warrants issuable under the Convertible
Loan Agreements are exercisable at $4.00 per ADS and have a term of three years from the issuance date. The warrants are subject
to adjustments upon certain events, including share splits, share dividends, subsequent rights offerings, and fundamental transactions.
In addition, until the three-year anniversary of the first closing date, in the event of certain subsequent equity issuances at
a price that is lower than the then applicable exercise price, the exercise price shall adjust to such lower price.
Concurrently with the execution of the
Convertible Loan Agreements, the Company entered into Registration Rights Agreements with each of Ami Sagi and the U.S.
Investors, pursuant to which the Company granted certain demand and piggyback registration rights with respect to the ordinary
shares represented by the ADSs underlying the convertible loans and warrants.
Following Shareholder Approval, as a result
of certain anti-dilution adjustment provisions, the Company will issue to Alpha Capital Anstalt, Ami Sagi, and Meitav Dash Provident
Funds and Pension Ltd. an aggregate amount of approximately 450,000 ADSs representing 450,000 ordinary shares and, in addition,
the exercise price of the warrants held by these shareholders will be adjusted to $4.00 per share.
The securities issued or issuable to Ami
Sagi are being offered and sold in an offshore transaction in reliance upon an exemption from registration requirements of Regulation
S promulgated under the Securities Act of 1933, as amended (the “Securities Act”). The securities issued or issuable
to the U.S. Investors are being offered and sold pursuant to an exemption from the registration requirements under Section 4(a)(2)
of the Securities Act and Rule 506 of Regulation D promulgated thereunder.
Attached hereto as Exhibit 99.1 and
incorporated by reference herein is a press release issued by the Company entitled “CollPlant Biotechnologies Raising $5.5 Million.”
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
COLLPLANT BIOTECHNOLOGIES LTD.
|
|
|
|
Date: September 3, 2019
|
By:
|
/s/ Eran Rotem
|
|
|
Name: Eran Rotem
|
|
|
Title: Deputy CEO and Chief Financial Officer
|
3
CollPlant Biotechnologies (NASDAQ:CLGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
CollPlant Biotechnologies (NASDAQ:CLGN)
Historical Stock Chart
From Sep 2023 to Sep 2024